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Abstract: Nutrition is an important factor in the treatment of patients in critical care. Potential hyper-
rmetabolism means underfeeding may cause malnourishment, while overfeeding increases risk of 
hyperglycemia and the associated physiological impact. Hyperglycemia can be treated through accurate 
glycemic control (AGC), and this paper examines the link between nutrition and achievement of AGC. 
Clinically validated virtual trials were carried out on the 371 patients in the SPRINT cohort using STAR, 
an adaptive AGC protocol targeting 80-145mg/dL. Nutrition results were compared to the rates given 
clinically to investigate the effect modulating nutrition has on the final level of nutrition administered. 
The effect of clinical nutrition stoppages on this level of nutrition was also isolated. The link between 
nutrition and the ability to achieve AGC was investigated by targeting STAR to both 80-145mg/dL and 
140-180mg/dL, allowing STAR to modulate nutrition as well as delivering constant rates of 60%, 80%, 
100%, 120% and 140% ACCP goal. Performance was assessed as %BG within the target range, 
hyperglycemia as %BG above the range and clinical workload as the number of BG measurements. 
Relative tightness was estimated using BG IQR. As expected, modulating nutrition led to a range of total 
nutrition delivered to patients. Importantly, low nutrition administration corresponded to low insulin 
sensitivity, and clinical nutrition stoppages were shown to drop median nutrition rates by 10% over the 
first 4 days in ICU, suggesting a significant effect if a nutrition target is desired. Variable nutrition in 
STAR was shown to lead to reduced BG variability and clinical workload, and different nutrition rates 
showed significant differences in BG outcomes despite the adaptive STAR framework. Combined, these 
results show that AGC could be better achieved with less effort if variable nutrition was permitted. In 
part, this effect is due to constant nutrition restricting the ability of a protocol to respond to low insulin 
sensitivity. Constant nutrition will also have a strong effect on the ability to target a specific range. 
Keywords: Decision support and control; Healthcare Management, Disease control, Critical care.
1. INTRODUCTION 
Critically ill patients are often referred to as being 
hypermetabolic and hyperglycaemic. It is known that 
hyperglycaemia is associated with worsened outcomes 
(Krinsley, 2003) and can have significant physiological 
impact (Horvath et al., 2008). A similar impact on physiology 
is assumed for hypermetabolism (Chiolero et al., 1997). 
There are concerns that hypermetabolic patients become 
malnourished, so nutrition practices for the critically ill have 
been the focus of numerous studies (Hegazi and Wischmeyer, 
2011).  
Nutrition and glycemic control form an integrated system, 
where insulin is used to balance nutritional intake against 
glycemic levels. The ideal levels of glycemia and nutritional 
intake are presently under debate. In particular nutrition 
modulation has been shown to be efficacious in achieving 
accurate glycemic control in highly insulin resistant or highly 
dynamic critically ill patients. However, persistent low-
calorie feeding may cause under-fed conditions, with 
concomitant increases in risk of morbidity, 
This paper investigates the multi-factorial link between target 
glycemic levels and nutrition rates, including both the effect 
of nutrition rates on ability to target glycemic level and the 
influence of variable nutrition in glycemic. In particular 
nutrition given to patients during the SPRINT study are 
investigated to determine the relative contributions of 
nutrition modulation for AGC and clinical stoppages of 
nutrition to overall calorie intake. The STAR protocol is able 
to target different levels of glycemia. However, limits on 
nutrition inputs can prevent achieving a desired glycemic 
level, and simulations are used to explore the limits of 
glucose levels versus nutrition intake. 
2. METHODS 
2.1  Model 
The clinically validated Intensive Care Insulin-Nutrition-
Glucose (ICING) metabolic model was used to simulate the 
fundamental metabolic dynamics (Lin et al., 2011). Table I 
lists the population constants of the model defined. 
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where G(t) [mmol/L] is the total plasma glucose, I(t) [mU/L] 
is the plasma insulin and interstitial insulin is represented by 
Q(t) [mU/L]. Exogenous insulin input is represented by uex(t) 
[mU/min] and endogenous insulin production is estimated 
with uen [mU/min], modeled as a function of plasma glucose 
concentration determined from critical care patients with a 
minimum pancreatic output of 1U/hr. P1 [mmol] represents 
the glucose in the stomach and P2 [mmol] represents glucose 
in the gut. Enteral glucose input is denoted P(t) [mmol/min]. 
2.2  Virtual Patients 
Clinically validated virtual trials (Chase et al., 2010) were 
carried out using the SPRINT AGC cohort clinical data 
(Chase et al., 2008) to create virtual patients. Virtual patients 
are created using clinical data to identify an hourly treatment-
independent insulin sensitivity profile SI(t) (Hann et al., 
2005), allowing virtual trials to realistically simulate patient 
response to a given (modified) treatment. This approach has 
been clinically validated on independent matched cohort data 
(Chase et al., 2010) and in several AGC trials (Penning et al., 
2011, Evans et al., 2011). Patient demographics are given in 
Table II.  
Patients were considered to require AGC once BG > 
7.0mmol/L, and this value was used to determine the 
beginning of a virtual trial. Interruptions in nutrition are 
common for some patients in clinical practice, and are 
incorporated by setting P(t) = 0 mmol/min over the same 
periods they occurred in the clinical data. Equally, clinically 
specified parenteral nutrition (PN) was included in the 
simulations at rates as decided clinically. 
2.3  Virtual Trials 
Virtual trials were carried out using STAR with a target range 
of both 80-145mg/dL and 140-180mg/dL (Evans et al., 
2011). These target levels match recent trials on glycemic 
control targets (Preiser and Devos, 2007, Finfer et al., 2009). 
To isolate the effect of nutrition on the ability to target 
glycemia, versions of STAR were also run on each target 
with the enteral nutrition rate set to 60%, 80%, 100%, 120% 
and 140% ACCP goal (Cerra et al., 1997). 
2.4 Analyses/Performance Metrics 
Nutrition in both the clinical SPRINT trial and STAR virtual 
trial was analysed over the first 4 days using ten-decile plots 
to outline the distribution of nutrition rates over the cohort of 
patients. These analyses were made inclusive and exclusive 
of clinical nutrition stoppages to highlight the effect of 
clinical conditions. The relationship between per-patient 
median SI and mean enteral nutrition rate was investigated to 
find what conditions led to low nutrition. 
Global cohort statistics were generated and compared for 
each of the virtual trials. Performance was defined as 
percentage of BG within selected glycemic bands, as well as 
percentage of BG above/below the target. Clinical effort was 
evaluated by BG measurement frequency as a surrogate 
(Aragon, 2006). BG data was resampled hourly to provide a 
consistent time-basis for comparison across protocols with 
different measurement and intervention intervals, and clinical 
stoppages account for around 10% of the total nutrition rates 
3. RESULTS 
Figures 1 and 2 use ten-decile plots of total nutrition given to 
SPRINT patients, and to virtual patients created from this 
cohort using STAR. Contrast between the plots inclusive and 
exclusive of nutrition stoppages indicate that clinical inability 
to feed patients has a significant effect on the overall 
nutrition rate. 
The SPRINT nutrition profile (exclusive of zero nutrition 
periods) is as expected by the design of the protocol, which 
targeted moderate nutrition rates to avoid overfeeding 
(Lonergan et al., 2006). Similarly, the STAR nutrition profile 
displays the effect of design for higher nutrition rates when 
practicable. 
Figures 3-4 indicate both STAR and SPRINT have a robust 
trend lowering nutrition when low SI is identified. SPRINT 
has a much wider scatter at higher SI, indicating less well-
defined behavior when presented with higher insulin 
sensitivity. STAR has a strong correlation between nutrition 
rate and SI. Nutrition is maintained at moderately high rates 
TABLE II 
PATIENT DEMOGRAPHICS 
 SPRINT cohort 
Total patients 371 
Age (years) 65 [49 – 74] 
% Male 63.6% 
APACHE II score 18 [15 – 24] 
APACHE II risk of death 25.7% [13.1% - 49.4%] 
Diabetic history 62 (16.7%) 
   
 
TABLE I 
CONSTANTS USED IN SYSTEM MODEL OF EQUATIONS (1)-(6) 
Model 
var. 
Description Numerical value [typical range] 
pG Endogenous glucose clearance 0.006 min-1 
SI Insulin sensitivity 
[1x10-7-1x10-2] 
L/(mU.min)a 
αG 
Saturation of insulin-dependent glucose 
clearance and receptor-bound insulin 
clearance from interstitium 
1/65 L/mU 
d1 Rate of glucose transfer between the stomach and gut -ln(0.5)/20 
d2 Rate of glucose transfer from the gut to the bloodstream -ln(0.5)/100 
Pmax Maximum disposal rate from the gut 6.11 mmol/min 
EGPb 
Basal endogenous glucose production 
(unsuppressed by glucose and insulin 
concentration) 
1.16 mmol/min 
typically 
CNS Non-insulin mediated glucose uptake by the central nervous system 0.3 mmol/min 
VG Glucose distribution volume 13.3 L 
nI, nC 
Rate of transport between plasma and 
interstitial insulin compartments 0.0075 min
-1 
αI 
Saturation of plasma insulin clearance by 
the liver 1.7x10
-3
 L/mU 
VI Insulin distribution volume 4.0 L 
xL First-pass hepatic insulin clearance 0.67 
nK 
Clearance of insulin from plasma via the 
renal route 0.0542 min
-1 
nL 
Clearance of insulin from plasma via the 
hepatic route 0.1578 min
-1 
aInsulin sensitivity (SI) is identified from clinical data in the range shown. 
 
  
 
until a threshold is reached, below which, reductions in SI 
correspond to reductions in nutrition rate. While SPRINT 
tended to use lower nutrition rates more often, STAR only 
restricted nutrition to below 60% when SI was very low.  
Table III presents statistics from virtual trials of STAR 
alongside constant-nutrition versions, targeting both the 
design range (80-145 mg/dL) and a raised target (140-180 
mg/dL). These statistics are supported by the cumulative 
density plots in Figure 5. 
At the 80-145mg/dL target, lower nutrition rates correspond 
with tighter control, as well as improved performance and 
safety. Higher nutrition rates are countered by increased 
insulin. When the target is raised, the 60% version is 
incapable of targeting the range, giving zero insulin and still 
displaying the lowest performance (performance peaks at the 
100% version for the constant nutrition versions).  
Median insulin is zero for all protocols at the higher target, 
suggesting modulation of nutrition is critical for control in 
this range. This suggestion is reinforced by workload and 
performance, with variable nutrition STAR achieving the 
highest performance with clinical effort a minimum of 10% 
below the lowest effort for a constant-nutrition protocol. 
Comparison of results from the constant-nutrition protocol at 
the raised target suggest that 100% ACCP goal would be 
required to target this range, with this protocol showing 
comparatively higher performance, tighter control and lower 
clinical effort. Variable nutrition STAR results indicate that 
actively varying nutrition allows for higher nutrition rates 
without compromising performance, and suggests that 
nutrition is an important tool to use when insulin is not able 
to provide sufficient control. 
4. DISCUSSION 
This research is a first investigation of the relationship 
between glycemic control and nutrition. The first statement is 
both intuitive and important: allowing an AGC protocol to 
modulate nutrition rate will result in a distribution of 
nutrition inputs to each patient. Thus, AGC protocols affect 
nutrition, or should (Suhaimi et al., 2010). 
More significantly, nutrition rates are influenced by clinical 
conditions. Figure 1 shows that nutrition stoppages 
significantly alter the nutrition profile. After these influences 
are removed, the figures show SPRINT targets a moderate 
nutrition rate, and the resulting rates are distributed across the 
allowable range. The equivalent effect on STAR, seen in 
Figure 2, show a protocol biased towards higher nutrition 
rates (by design). Less than 30% of patients had a median 
feed rate less than 60% over the first four days under STAR, 
compared with approximately 50% under SPRINT. 
Comparison indicates it is possible to design a protocol using 
variable nutrition that, while not guaranteeing a specific 
A) 
 
B) 
 
Figure 1. Ten-decile plots of nutrition given to SPRINT patients over the first four days of their stay in ICU, both inclusive (A) and exclusive (B) of 
periods where nutrition input was suspended for clinical reasons 
 
A) 
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Figure 2. Ten-decile plots of nutrition given to virtual patients of the SPRINT cohort under the STAR protocol over the first four days of their stay in 
ICU, both inclusive (A) and exclusive (B) of periods where nutrition input was suspended for clinical reasons 
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nutrition rate for a specific patient, will have a preference for 
a particular nutrition profile and will only deviate under 
specific conditions. 
SPRINT uses a wide range of nutrition behavior, as 
suggested by the distribution in Figure 1.B and reinforced by 
Figure 3. SPRINT lowers nutrition rates when patients are 
insensitive to insulin, but more sensitive patients did not 
consistently receive higher nutrition rates. 
The bias towards higher nutrition in Figure 2.B shows STAR 
can provide control with raised nutrition. Figure 4 indicates 
that behavior is very uniform, with nutrition maintained at a 
high (median 80% ACCP goal) level unless insulin 
sensitivity is low. The sharpness of the nutrition reduction 
indicates the threshold had been increased. A steeper 
reduction in Figure 4 than 3 indicates STAR maintains higher 
nutrition rates for less sensitive patients than SPRINT. 
Combined, these results indicate that while AGC protocols 
influence the nutrition delivered to a patient, this effect can 
be controlled. A desirable behavior can be developed, though 
clinical conditions will have a significant effect. 
The converse also applies. The virtual trials isolated the 
effect of nutrition rates on AGC by preventing STAR from 
modulating nutrition while targeting two different ranges. 
STAR is uniquely placed to carry out these styles of 
investigations, as the adaptable risk-based protocol is 
designed to respond to any clinical requirements.  
Across both targets, median BG rose together with rises in 
nutrition rate. This observation indicated that nutrition is 
likely to influence how well an AGC protocol can reach a 
target whilst effectively modulating insulin only, making a 
case for taking nutrition into account when designing a 
protocol (Suhaimi et al., 2010). 
However, the highest performance and lowest workload at 
the raised target was clearly exhibited by variable-nutrition 
STAR, indicating a likely advantage with the ability to “fine-
tune” glycemia with nutrition. Controlling BG with nutrition 
appears more significant when a higher target is desired, 
particularly as external insulin was often not given. 
Constant nutrition rates reduce performance and increase the 
incidence of hyperglycemia. Workload is also compromised 
as nutrition rate increases, indicating more work is required 
to maintain patients at a given target. The likely explanation 
 
 
Figure 3. Scatter of SPRINT per-patient SI and % ACCP goal feed over the first four days of their stay in ICU, exclusive of patients who were not 
enterally fed. Separate trend-lines were fitted above/below a threshold SI of 3x10-3 to indicate different behaviour at high and low insulin sensitivities. 
 
Figure 4. Scatter of STAR per-patient SI and % ACCP goal feed over the first four days of their stay in ICU, exclusive of patients who were not enterally 
fed. Separate trend-lines were fitted above/below a threshold SI of 3x10-3 to indicate different behaviour at high and low insulin sensitivities. 
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corresponds to Figures 4 and 5. Constant nutrition rates 
remove the ability of STAR to respond sufficiently to 
patients with low insulin sensitivity, where nutrition rates 
would typically. For these patients, additional insulin would 
have a limited effect, and the upper limit on insulin under 
STAR (Evans et al., 2011) prevents further increases. This 
would also explain the reduced tightness of BG control for 
each of the constant nutrition versions. 
 
A final reason for incorporating nutrition into the design of 
an AGC protocol rests on generalizing protocols across 
institutions. Different critical care providers have different 
standard practices relating to nutrition levels, and even an 
adaptable protocol such as STAR is unable to avoid different 
nutrition rates influencing the quality of control provided. 
Adaptability appears particularly important due to the effect 
clinical stoppages have on the actual nutrition delivered to the 
patient. 
Table III. Statistics from STAR virtual trials at different targets, including constant nutrition versions ranging from 60% - 140% ACCP goal feed 
STAR 60% 80% 100% 120% 140% 
Target: 80 - 145 mg/dL 
# BG measures: 20999 21248 22175 23560 24926 26390 
BG median [IQR] (mg/dL) 
106 
[97.2- 118] 
106 
[97.1-117] 
107 
[97.5-119] 
108 
[97.8-122] 
109 
[98.2-125] 
110 
[98.7-129] 
% BG < band 3.14 2.78 2.99 3.13 3.33 3.54 
% BG within band 90.7 91.0 89.2 86.9 84.0 80.9 
% BG > band 1.60 1.78 2.37 3.06 3.97 5.29 
# patients < 40mg/dL 9 6 5 8 9 11 
Median insulin rate [IQR] 
(U/hr): 
2.5 
[1.5 - 4.5] 
2.0 
[1.0 - 3.5] 
2.5 
[1.5 - 4.5] 
3.0 
[1.5 - 5.5] 
3.5 
[2.0 - 6.0] 
4.0 
[2.0 - 7.0] 
Median glucose rate [IQR] 
(g/hour): 
4.8 
[2.0 - 6.5] 
3.9 
[2.9 - 4.2] 
5.2 
[3.8 - 5.6] 
6.5 
[4.8 - 7.0] 
7.8 
[5.8 - 8.4] 
9.2 
[6.7 - 9.8] 
Median glucose rate [IQR] 
(% goal): 
80.0 
[30 - 100] 
60.0 
[60 - 60] 
80.0 
[80 - 80] 
100.0 
[100 - 100] 
120.0 
[120 - 120] 
140.0 
[140 - 140] 
Target: 140 - 180 mg/dL 
# BG measures: 30106 35171 34571 33286 34201 34308 
BG median [IQR] (mg/dL) 
154 
[139-165] 
147  
[133-160] 
152  
[137-165] 
156  
[141-169] 
160  
[144-173] 
162 
[146-177] 
% BG < band 26.3 37.0 29.3 24.3 21.4 19.2 
% BG within band 66.9 58.7 63.4 64.5 62.6 59.7 
% BG > band 6.82 4.32 7.32 11.23 16.06 21.06 
# patients < 40mg/dL 1 1 1 1 1 1 
Median insulin rate [IQR] 
(U/hr): 
0.0  
[0.0 - 0.0] 
0.0  
[0.0 - 0.0] 
0.0  
[0.0 - 1.0] 
0.0  
[0.0 - 1.0] 
0.0  
[0.0 - 1.5] 
0.0  
[0.0 - 1.5] 
Median glucose rate [IQR] 
(g/hour): 
4.9  
[2.2 - 6.5] 
3.9  
[2.9 - 4.2] 
5.2  
[3.8 - 5.6] 
6.5  
[4.8 - 7.0] 
7.8  
[5.8 - 8.4] 
9.2  
[6.7 - 9.8] 
Median glucose rate [IQR] 
(% goal): 
80.0 
[35 - 100] 
60.0 
[60 - 60] 
80.0 
[80 - 80] 
100.0 
[100 - 100] 
120.0 
[120 - 120] 
140.0 
[140 - 140] 
 
 
Figure 5. Cumulative density plots of STAR (dotted lines), including constant nutrition versions (from left to right, 60%, 80%, 100%, 120% 140%) 
at both the typical target of 80-145 mg/dL and a raised target of 140-180 mg/dL. 
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5. CONCLUSIONS 
Ability to achieve a glycemic target is influenced by nutrition 
rate, suggesting nutrition should be directly incorporated into 
the design of an AGC protocol. Also, nutrition targets are 
significantly affected by clinical nutrition stoppages. Finally, 
with robust design, modulating nutrition can allow an AGC 
protocol to reduce workload, achieve tighter control and 
target different glycemic ranges. 
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